A denosine has a long history of involvement in cardiac function. It was first purified from mammalian heart homogenates in 1929 by Drury and Szent-Györgyi, 1 who reported a "suppressive" action of adenosine on the heart, including decreased heart beat rate and perfusion pressure, 1 now termed bradycardia and coronary artery vasodilation, respectively. Based on a variety of experimental results from several laboratories, Berne et al proposed in the early 1960s that adenosine plays an important role in the adjustment of blood flow to the metabolic requirements of organs, including the heart, brain, and skeletal muscle. 2 Numerous studies now support the hypothesis that adenosine can be directly released or generated from released ATP/ADP in the heart during ischemia, causing increased oxygen and nutrition supply by inducing coronary artery relaxation. 3 Although adenosine exhibits reuptake via specific adenosine transporters, many, if not all, of the biological effects of adenosine are believed to be mediated by adenosine receptors (ARs), of which 4 subtypes (A 1 R, A 2A R, A 2B R, and A 3 R) have been cloned and pharmacologically characterized. 4 The diverse physiological functions mediated by the different AR subtypes, particularly in the modulation of the cardiovascular system, have been confirmed by genetically engineered mice. 4 Null mice have been generated for each of the AR subtypes, and none of the 4 ARs plays a critical role during development. 4,5 Although each AR protein had been thought to exist in the cell membrane as a monomer, recent studies with recombinant expression systems have revealed that some of the AR subtypes heterodimerize with other G-protein coupled receptors. For example, A 1 R has been shown to heterodimerize with the P2Y 1 receptor 6 and with the D 1 dopamine receptor, 7 and A 2A R heterodimerizes with the D 2 dopamine receptor. 8 However, it remains unknown whether any endogenous ARs exist as heterodimers in the cardiovascular system.
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Adenosine is best known for its vasorelaxant effect, which has been intensively studied for the past several decades. Findings include: (1) in most blood vessels, including the coronary artery, adenosine is a potent vasodilator via activa-tion of A 2A R and/or A 2B R, which are expressed by both the endothelium and smooth muscle; 9 (2) in some branches of the pulmonary arteries and in renal afferent arterioles, adenosine functions as a potent vasoconstrictor, which is mediated exclusively by activation of A 1 R; 9,10 (3) A 1 R is also expressed in coronary artery smooth muscle, which limits adenosineinduced coronary dilatation via A 2A R and A 2B R 11 ; (4) it appears that vascular endothelial cells do not express appreciable A 1 R and A 3 R, 12 which supports the view that adenosine-induced endothelium-dependent relaxation is mediated by A 2A R and/or A 2B R 13 ; and finally (5) the A 3 R is expressed in some vascular smooth muscle, although its exact physiological function has not been conclusively determined. 14 In addition to its acute effects, adenosine also has significant impact on vascular cell growth. 15 For example, adenosine stimulates vascular endothelial cell growth through the A 2 type adenosine receptors. 16 In vascular smooth muscle cells, adenosine originally was solely described as antimitogenic via activation of A 2B R. 17 However, recent studies have demonstrated that adenosine functions as a mitogen in coronary artery smooth muscle cells via A 1 R. 18, 19 This apparent discrepancy was reconciled by experimental evidence indicating a differential expression profile of the four ARs in aorta versus coronary arteries. 18, 19 Thus, both the acute and chronic effects of adenosine are not uniform, partially because of the complexity of AR expression patterns in different blood vessels.
Accumulating evidence indicates that adenosine is also important in neovascularization, including angiogenesis and vasculogenesis, which in the heart, contributes to the wellknown cardioprotective effects of adenosine in response to chronic ischemia or hypoxia. 20 The proneovascularization action of adenosine has been documented to occur via multiple mechanisms. For example, adenosine is known to stimulate vascular endothelial cell proliferation, migration, and tube formation in vitro. 15 In addition, adenosine stimulates synthesis of proangiogenic molecules, such as vascular endothelial growth factor, interleukin-8, and angiopoetin-1 in endothelial cells, monocytes, and macrophages. 15, 20 It is now clear that all 4 ARs are involved in the process of angiogenesis and/or vasculogenesis 20 ; however, the contribution of the individual AR depends on the cell type and animal model used. 21 Perhaps, the most convincing study in this respect is that of A 2A R-knockout mice, which exhibit diminished blood vessel formation in healing skin wounds. 22 In this issue of Circulation Research, Ryzhov et al 23 have addressed a new question concerning the role of adenosine in endothelial progenitor cell (EPC) homing to cardiac endothelium (Figure) . In this elegant study, the authors have made several significant observations: (1) stimulation of ARs for just 5 minutes in murine embryonic EPCs (eEPCs) and mouse cardiac microvascular endothelial cells (MCECs) increased eEPC adhesion to MCECs under static and flow conditions. A similar effect of adenosine was observed in the interaction of human adult culture-expanded EPCs and human cardiac microvascular endothelial cells; (2) these cell culture observations were confirmed in isolated mouse hearts that were perfused with adenosine, followed by an eEPC suspension, leading to increased eEPC retention in periendothelial areas;
(3) the authors also determined that eEPCs and MCECs preferentially express functional A 1 R and A 2B R, respectively (Figure) , and that both receptors are involved in the enhanced cell-cell interaction; and, finally, (4) the authors showed that stimulation of AR in MCECs induced rapid cell surface expression of P-selectin, which binds to its ligand (P-selectin glycoprotein ligand-1) in eEPCs, leading to enhanced cellcell adhesion (Figure) . These original findings provided new insight into our understanding of the role of adenosine in vasculogenesis, a process in which EPC homing is crucial.
It should be noted, however, that some of the present findings are not consistent with the literature. For example, in A 2B R-deficient mice, the adhesiveness of the mesenteric arteries was increased, with increased expression of several adhesion molecules in endothelium, including P-selectin, E-selectin, and intracellular adhesion molecule-1, 5 suggesting that A 2B R activation in vivo may have a suppressive effect on cell adhesion to vascular endothelium, which contrasts with the main finding of the present study. Using a mouse skin wound model, others have demonstrated the predominant role of A 2A R in promoting angiogenesis and vasculogenesis. 22 These discrepancies may be explained by differences in tissues/organs; however, continued research using A 2B Rdeficient mice should assist in further testing of the model generated by the present study.
It is of great interest to know that eEPCs selectively express A 1 R (Figure) , which plays a role in eEPC adhesion, although it appears not as significant as A 2B R in cardiac endothelium as evidenced by a much lesser inhibitory effect of an A 1 R blocker than an A 2B R blocker on eEPC adhesion. 23 Future studies may address how activation of A 1 R affects the eEPC phenotype and whether increasing endogenous adeno-sine levels by suppressing adenosine degradation and/or uptake systems could boost the adhesion and retention of EPCs in experimental models. The postreceptor signaling mechanisms underlying A 1 R-and A 2B R-mediated eEPC adhesion also remain to be determined.
In terms of pharmacological intervention, an A 2B Rselective agonist may have some advantage over adenosine, which is known to cause bradycardia and atrioventricular blockage mediated by A 1 R. In a word, the present study 23 provides a new concept of using adenosine as an alternative approach to enhance the efficacy of cell-based therapy for ischemic heart disease.
Figure.
Adenosine stimulation of EPC adhesion to cardiac microvascular endothelial cells (CMEC). Circulating EPCs selectively express the A 1 R, whereas the cardiac microvascular endothelial cells preferentially express the A 2B R. 23 In ischemic or hypoxic conditions, adenosine is accumulated surrounding the ischemic loci. Adenosine then activates the A 1 R and A 2B R, respectively. A 2B R activation induces exocytosis of endothelial Weibel-Palade bodies (WPB), leading to surface expression of P-selectin, which binds to P-selectin glycoprotein ligand-1 (PSGL-1) constitutively expressed on EPCs. 23 
